These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24559127)

  • 1. New treatment options for chronic lymphocytic leukemia.
    Delgado J; Baumann T; Santacruz R; Montserrat E
    Expert Opin Pharmacother; 2014 Apr; 15(6):823-32. PubMed ID: 24559127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic lymphocytic leukemia therapy: beyond chemoimmunotherapy.
    Delgado J; Baumann T; Ghita G; Montserrat E
    Curr Pharm Des; 2012; 18(23):3356-62. PubMed ID: 22591384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising therapies for the treatment of chronic lymphocytic leukemia.
    Morabito F; Recchia AG; Vigna E; De Stefano L; Bossio S; Morabito L; Pellicanò M; Palummo A; Storino F; Caruso N; Gentile M
    Expert Opin Investig Drugs; 2015 Jun; 24(6):795-807. PubMed ID: 25728009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Itchaki G; Brown JR
    Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
    Vitale C; Falchi L; Ten Hacken E; Gao H; Shaim H; Van Roosbroeck K; Calin G; O'Brien S; Faderl S; Wang X; Wierda WG; Rezvani K; Reuben JM; Burger JA; Keating MJ; Ferrajoli A
    Clin Cancer Res; 2016 May; 22(10):2359-67. PubMed ID: 26733610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.
    Riches JC; Gribben JG
    Curr Cancer Drug Targets; 2016; 16(8):689-700. PubMed ID: 27055579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge.
    Smolej L
    Curr Cancer Drug Targets; 2016; 16(8):701-709. PubMed ID: 27055577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving treatment for patients with chronic lymphocytic leukemia.
    Shanafelt TD
    Hematology; 2012 Apr; 17 Suppl 1():S133-6. PubMed ID: 22507801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging immunological drugs for chronic lymphocytic leukemia.
    Robak P; Smolewski P; Robak T
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):423-47. PubMed ID: 26153226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
    Spina F; Rezzonico F; Farina L; Corradini P
    Eur J Haematol; 2013 Apr; 90(4):340-4. PubMed ID: 23281656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
    Mato A; Jauhari S; Schuster SJ
    Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents for chronic lymphocytic leukemia.
    Wu M; Akinleye A; Zhu X
    J Hematol Oncol; 2013 May; 6():36. PubMed ID: 23680477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.
    Byrd JC; Lin TS; Grever MR
    Semin Oncol; 2006 Apr; 33(2):210-9. PubMed ID: 16616068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Gentile M; Recchia AG; Vigna E; Mazzone C; Lucia E; Gigliotti V; Bossio S; Madeo A; Morabito L; Servillo P; Franzese S; Caruso N; De Stefano L; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Feb; 20(2):273-86. PubMed ID: 21214505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
    Giannopoulos K; Mertens D; Stilgenbauer S
    Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in therapy of chronic lymphocytic leukaemia.
    Routledge DJ; Bloor AJ
    Br J Haematol; 2016 Aug; 174(3):351-67. PubMed ID: 27291144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
    Brown JR
    Leuk Lymphoma; 2010 Aug; 51(8):1382-5. PubMed ID: 20624030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
    Lin TS
    Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S137-43. PubMed ID: 18952544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies in the treatment of chronic lymphocytic leukemia.
    Liu NS; O'Brien S
    Med Oncol; 2004; 21(4):297-304. PubMed ID: 15579912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.